Stockscreener 앱 받기
535.57
2.10%
-11.49
시간 외 거래:
535.57
전일 마감가:
$547.06
열려 있는:
$541.47
하루 거래량:
294.66K
Relative Volume:
0.65
시가총액:
$22.73B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
19.77
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
-2.13%
1개월 성능:
-1.90%
6개월 성능:
+12.31%
1년 성능:
+81.23%
1일 변동 폭
$530.09
$543.05
1주일 범위
$530.09
$563.70
52주 변동 폭
$272.12
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
535.57 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.49 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.86 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.18 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.39 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics director Jan Malcolm sells $178,941 in stock - Investing.com UK
United Therapeutics director Jan Malcolm sells $178,941 in stock By Investing.com - Investing.com Australia
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Form 4 United Therapeutics Corporation For: 10 July By Investing.com - Investing.com South Africa
UTHR Stock Quote Price and Forecast - CNN
United Therapeutics CEO Martine Rothblatt sells $5.2m shares By Investing.com - Investing.com Australia
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $5.2m shares - Investing.com
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m - Investing.com
Form 4 United Therapeutics Corporation For: 9 July By Investing.com - Investing.com Canada
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know - TradingView
United Therapeutics: CEO's Multi-Million Dollar Sales Signal Caution Amidst Bullish Consensus - Kavout | AI
United Therapeutics CEO Martine Rothblatt sells $5.3m company stock - Investing.com
Form 4 United Therapeutics Corporation For: 8 July By Investing.com - Investing.com South Africa
United Therapeutics CEO Martine Rothblatt sells $5.3m company stock By Investing.com - Investing.com Nigeria
Is United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation? - Insider Monkey
United Therapeutics expands immune therapy pipeline with Thymmune - BioBuzz
United Therapeutics focuses on pulmonary arterial hypertension. Nasdaq-listed biotech builds on its - Ad-hoc-news.de
United Therapeutics Corp (UTHR) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100 - GuruFocus
United Therapeutics CEO Rothblatt sells $5.2m in company stock By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 7 July By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.2m in company stock - Investing.com
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy - Seeking Alpha
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises (NASDAQ:RGC) - Seeking Alpha
RTP drugmaker strikes $300M deal for Massachusetts company - The Business Journals
United Therapeutics EVP Paul Mahon sells $4.87m in common stock - Investing.com
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics Buys Thymmune For Up To $300M - Law360
Thymmune Therapeutics acquired by Maryland biotech for $140M - The Business Journals
United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M - The Business Journals
United Therapeutics Expands Immune Therapy Pipeline With Thymmune - Benzinga
United Therapeutics (UTHR) Expands Portfolio with Thymmune Thera - GuruFocus
United Therapeutics (UTHR) Acquires Thymmune Therapeutics for $1 - GuruFocus
United Therapeutics Expands Regenerative Medicine Pipeline with $140M Thymmune Acquisition - citybiz
United Therapeutics buys Thymmune, adding thymus cell therapy platform - Stock Titan
The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026 - Morningstar
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock - Investing.com UK
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 30 June By Investing.com - Investing.com Nigeria
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs - Sahm
Big Pharma Has a Case of Merger Mania - The Motley Fool
United Therapeutics Corporation 8-K Filing Details: Stock Incentive Plan, Key Shareholder Info & SEC Compliance (June 2026) – Minichart - Minichart
FDA approves United Therapeutics’ LungFX lung perfusion device By Investing.com - Investing.com South Africa
United Therapeutics (UTHR) Secures FDA Approval for LungFX - GuruFocus
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MALCOLM JAN | Director |
Jul 09 '26 |
Option Exercise |
0.00 |
650 |
0 |
775 |
| MALCOLM JAN | Director |
Jul 10 '26 |
Sale |
550.59 |
325 |
178,942 |
450 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 09 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 09 '26 |
Sale |
551.13 |
9,500 |
5,235,756 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 08 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 08 '26 |
Sale |
553.17 |
9,500 |
5,255,111 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 07 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 07 '26 |
Sale |
558.87 |
9,500 |
5,309,296 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 06 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 06 '26 |
Sale |
548.96 |
9,500 |
5,215,133 |
40,513 |
0.74%
1.70%
자본화:
|
볼륨(24시간):